Bevacizumab in Post-acute Sequelae of COVID-19 : Efficacy and Safety (Pilot Study)
Bevacizumab in Post-acute Sequelae of COVID-19 : Efficacy and Safety (Pilot Study)
Not yet recruiting · NCT07089719 · Registry updated 2025-07-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Bevacizumab in Post-acute Sequelae of COVID-19 : Efficacy and Safety (Pilot Study) | COVID-19, Coronaviridae Infections, Infections, Nidovirales infectious disease, Orthocoronavirinae infectious disease, RNA Virus Infections, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Not yet recruiting | Phase 2 | 2025-07-28 | NCT07089719 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| ANRS, Emerging Infectious Diseases | 47 |
| Assistance Publique - Hôpitaux de Paris | 985 |
| Ministry of Health, France | 84 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| HEGP, clinical investigation center | Paris | France | 1 |
| HEGP, department of Physiology | Paris | France | 1 |